Lactobacillus reuteri NCIMB 30242 and Reduced Adverse Event Frequency

Doses used in studies

CFU/day: 5.8 billion (median 5.8 billion, IQR 5.8 billion–5.8 billion) — 1 study

Safety in these studies

Overall tolerabilityNo significant difference
No clinically significant differences between the probiotic capsule and placebo capsule treated groups were detected in either the blood clinical chemistry or hematology results.
from: Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplem
Overall tolerabilityReported
These results demonstrate that administration of a twice daily dose of 2.9×10⁹ CFU was safe and well tolerated in the population evaluated over 9 weeks.
from: Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplem

1 of 1 paper

Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial.